TURP術後尿路感染症に対するα-Chymotripsinの効果

Abstract

Lower urinary tract infection, frequently troublesome and difficult to eradicate, has been considered as an almost inevitable complication following transurethral prostatic resection. In an effort to treat this complication after transurethral prostatic resection, achymotripsin enteric-coated tablet, a pancreatic proteolytic enzyme, was administered to twenty patients and the result was compared to that of twenty-one control patients. The administration of the a-chymotripsin enteric-coated tablet was, as a rule, started two weeks after the transurethral prostatic resection with a dosage of 2 tablets 3 times a day (1 tablet contains 100 Ch. Ti. of a-chymotripsin) and was continued as long as the urinary tract infection had persisted. The duratio n of postoperative urinary tract infection in the a-chymotripsin treated group was 8.5 weeks on the average (varied from 5 to 15 weeks) which was 3.1 weeks shorter than that of the control group (11.6 weeks on the average, varied from 6 to 19 weeks). No unpleasant side effect occurred in this series, except for one patient who complained of a mild degree of loss of appetite during the treatment with a-chymotripsin enteric-coated tablet, which disappeared soon after the completion of the treatment. In conclusion, the use of a-chymotripsin enteric-coated tablet was believed to be an effective therapeutic measure for combating urinary tract infection following transurethral prostatic resection.